Community Practice Connections™: Are you Focusing on Chronic Kidney Disease? Evolving Treatment Strategies in Patients With Type 2 Diabetes

Released On
November 30, 2020

Expires On
November 30, 2021

Media Type

Completion Time
60 minutes

Endocrinology, Primary Care

Cardiovascular Disease, Diabetes, Heart Disease, Primary Care

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grant from Bayer Healthcare.

Credit Available

  • Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)
  • Nurses — 1.00 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward primary care clinicians who treat patients with diabetes. Nephrologists and other health care professionals interested in the treatment of CKD in patients with diabetes are also invited to participate.

Activity Overview

Diabetic kidney disease is a disease multiplier that increases the risk of stroke, cardiac, and vascular disease, yet almost half of patients with diabetes are not routinely screened to allow for diagnosis and appropriate treatment. Appropriate screening and treatment can prevent progression to end-stage renal disease and allow for the management of comorbid hypertension and other cardiovascular risk factors. Newer classes of antihyperglycemic agents have demonstrated both renal and cardiac benefits, and the first class of agents for treatment of chronic kidney disease (CKD) is emerging.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the virtual symposium at the Family Medicine Experience (FMX) American Academy of Family Physician’s annual meeting held October 13-17, 2020. This unique and engaging multi-media activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with diabetes and putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, you should be better able to:

  • Describe recommended screening and diagnostic practices for CKD in patients with type 2 diabetes mellitus
  • Evaluate the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists and other therapies under investigation for the treatment of CKD
  • Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression


Stephen A. Brunton, MD, FAAFP

Executive Director
Primary Care Metabolic Group
Los Angeles, CA

Lucia M. Novak, MSN, ANP-BC, BC-ADM

Co-Executive Director and Diabetes Expert
Capital Health and Metabolic Center
Capital Diabetes & Endocrine Associates
Silver Spring, MD

Robert C. Stanton, MD

Chief, Kidney and Hypertension Section, Joslin Diabetes Center
Associate Professor of Medicine, Harvard Medical School
Staff Physician, Beth Israel Deaconess Medical Center
Boston, MA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Stephen A. Brunton, MD, FAAFP

  • Consultant: Abbott Laboratories, AstraZeneca, Janssen, Bayer Healthcare, Novo Nordisk, Sanofi-Aventis, Xeris Pharmaceuticals
  • Speakers’ Bureau: Novo Nordisk, Sanofi-Aventis, Xeris Pharmaceuticals, Bayer Healthcare, Eli Lilly & Company, Novo Nordisk

Lucia M. Novak, MSN, ANP-BC, BC-ADM

  • Advisory Board: Novo Nordisk, Janssen, Sanofi-Aventis, Xeris Pharmaceuticals
  • Consultant: Abbott Diabetes Care, Novo Nordisk, Sanofi-Aventis, Xeris Pharmaceuticals
  • Speakers’ Bureau: Abbott Diabetes Care, AstraZeneca, Janssen, Novo Nordisk, Xeris Pharmaceuticals

Robert C. Stanton, MD, has no relevant financial relationships with commercial interests.

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.